8:00 – 8:15  Welcome/SARC Update  Laurence Baker

8:15 – 9:00  Chawla/Rosenfeld Developmental Therapeutics Symposium
From IGFR to mTor and Back Again: Targeting IGF Signaling in Sarcomas
Lee Helman

9:00-10:15  Review of Ongoing SARC Trials
SARC 003 Gemcitabine/Docetaxel in Bone Sarcoma    Shreyas Patel
SARC 004 Neoadjuvant Imatinib in DFSP            Scott Schuetze
SARC 005 Adjuvant Therapy High Risk Uterine Leiomyosarcoma  Robert Maki
SARC 006 MPNST: Sporadic versus NF1 associated  Lee Helman
SARC 007 Perifosine in chemoinensitive sarcoma  Joe Ludwig
SARC 009 Dasatinib in metastatic sarcoma  Scott Schuetze

Review of Pending Trials
SARC 010 Dasatinib in GIST  (TBD)
SARC 011 IGF-1R in selected sarcomas  Alberto Pappo
SARC 012 Src kinase Inhibitor Recurrent Osteosarcoma
Localizaed to Lung  Su Yoing Kim

10:15- 10:30  Break

10:30-12:00  Closed Session (Limited to attendees who have signed CDA with SARC)